Comparative analysis of IgG Responses to recombinant Qβ phage displayed MSP3 and UB05 in Dual HIV-malaria infected adults living in areas differing in Malaria transmission intensities
暂无分享,去创建一个
G. Nchinda | C. Esimone | E. Achidi | L. Kaptue | Arinze S Okoli | Arinze S. Okoli | W. Mbacham | Chae Gyu Park | P. Netongo | S. Bawage | G. Chukwuma | M. I. Okeke | A. B. Waffo | R. Megnekou | T. Tchouangueu | Carrie A. Sanders | A. Lissom | Loveline N. Ngu | Anna Gutiérrez | R. Leke | Herve F. Ouambo | Apeh A. Ngoh | Colince J. Tchadji | Ghislain Donald Njambe Priso | Rosario Garcia | M. Okeke | R. Garcia
[1] G. Nchinda,et al. Filaria specific antibody response profiling in plasma from anti-retroviral naïve Loa loa microfilaraemic HIV-1 infected people , 2018, BMC Infectious Diseases.
[2] S. Billong,et al. Prevalence and risk factors to HIV-infection amongst health care workers within public and private health facilities in Cameroon , 2018, The Pan African medical journal.
[3] S. Ghogomu,et al. Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate , 2018, Parasite immunology.
[4] G. Nchinda,et al. Phenotypic characterization of regulatory T cells from antiretroviral‐naive HIV‐1‐infected people , 2017, Immunology.
[5] G. Nchinda,et al. The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes , 2017, Biomedicine Hub.
[6] F. Osier,et al. Changes in Malaria Epidemiology in Africa and New Challenges for Elimination , 2016, Trends in parasitology.
[7] A. Njunda,et al. The prevalence of malaria in people living with HIV in Yaounde, Cameroon , 2016, BMC Public Health.
[8] Arlo Z. Randall,et al. Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya. , 2015, The Journal of infectious diseases.
[9] M. Laurens,et al. Vaccines against malaria. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] K. Badu,et al. The prevalence of malaria among HIV seropositive individuals and the impact of the co- infection on their hemoglobin levels , 2015, Annals of Clinical Microbiology and Antimicrobials.
[11] O. Doumbo,et al. Protection of Malian children from clinical malaria is associated with recognition of multiple antigens , 2015, Malaria Journal.
[12] D. Masiga,et al. High-resolution melting analysis reveals low Plasmodium parasitaemia infections among microscopically negative febrile patients in western Kenya , 2014, Malaria Journal.
[13] S. Aller,et al. In Vitro Evolution and Affinity-Maturation with Coliphage Qβ Display , 2014, PloS one.
[14] J. Kublin,et al. HIV-1 infection and antibodies to Plasmodium falciparum in adults. , 2014, The Journal of infectious diseases.
[15] M. Bouyou-Akotet,et al. Falciparum Malaria as an Emerging Cause of Fever in Adults Living in Gabon, Central Africa , 2014, BioMed research international.
[16] B. Lowe,et al. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria☆ , 2013, Vaccine.
[17] M. Christiansen,et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. , 2013, The Journal of infectious diseases.
[18] Miles P. Davenport,et al. The Dynamics of Naturally Acquired Immunity to Plasmodium falciparum Infection , 2012, PLoS Comput. Biol..
[19] Kevin Marsh,et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. , 2012, The Journal of clinical investigation.
[20] J. Ferro,et al. Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique , 2012, Malaria Journal.
[21] C. John,et al. Antibodies to Plasmodium falciparum Erythrocyte-binding Antigen-175 are Associated With Protection From Clinical Malaria , 2011, The Pediatric infectious disease journal.
[22] S. Cousens,et al. Protection against malaria by MSP3 candidate vaccine. , 2011, The New England journal of medicine.
[23] O. Doumbo,et al. A field trial to assess a blood-stage malaria vaccine. , 2011, The New England journal of medicine.
[24] Matthew A. Kayala,et al. Sterile Protective Immunity to Malaria is Associated with a Panel of Novel P. falciparum Antigens* , 2011, Molecular & Cellular Proteomics.
[25] D. Doolan,et al. Malaria vaccine design: immunological considerations. , 2010, Immunity.
[26] A. Cowman,et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] T. Theander,et al. Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh. , 2010, Vaccine.
[28] Jack S. Richards,et al. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.
[29] R. Noor,et al. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months , 2009, Malaria Journal.
[30] P. Druilhe,et al. Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Immunogenicity Studies in Models , 2009, Infection and Immunity.
[31] P. Gilson,et al. Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness , 2009, Infection and Immunity.
[32] C. Rogier,et al. Long-Term Clinical Protection from Falciparum Malaria Is Strongly Associated with IgG3 Antibodies to Merozoite Surface Protein 3 , 2007, PLoS medicine.
[33] Hong Zhou,et al. In Immunization with Plasmodium falciparum Apical Membrane Antigen 1, the Specificity of Antibodies Depends on the Species Immunized , 2007, Infection and Immunity.
[34] A. Nasr,et al. Fc gamma Receptor IIa (CD32) Polymorphism and Antibody responses to Asexual Blood‐stage Antigens of Plasmodium falciparum Malaria in Sudanese Patients , 2007, Scandinavian journal of immunology.
[35] Andrea Crisanti,et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. , 2007, Clinical chemistry.
[36] Aditi Gupta,et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Theisen,et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. , 2004, The Journal of infectious diseases.
[38] F. Ntoumi,et al. Sickle cell trait carriage: imbalanced distribution of IgG subclass antibodies reactive to Plasmodium falciparum family-specific MSP2 peptides in serum samples from Gabonese children. , 2002, Immunology letters.
[39] R. Anders,et al. Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.
[40] S. Hoffman,et al. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. , 2000, The American journal of tropical medicine and hygiene.
[41] F. Fumoux,et al. High Immunoglobulin G2 (IgG2) and Low IgG4 Levels Are Associated with Human Resistance to Plasmodium falciparum Malaria , 2000, Infection and Immunity.
[42] F. Lunel,et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages , 1995, The Journal of Experimental Medicine.
[43] A. Sabchareon,et al. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes , 1990, The Journal of experimental medicine.
[44] G. Nchinda,et al. Surface Engineering of the RNA Coliphage Qβ to Display Plasmodium Falciparum Derived Asexual Blood Stage Antigens UB05 and Merozoite Surface Protein 3 , 2018 .
[45] A. Amambua-Ngwa,et al. Isolation and expression of UB05, a Plasmodium falciparum antigen recognised by antibodies from semi-immune adults in a high transmission endemic area of the Cameroonian rainforest , 2009, Clinical chemistry and laboratory medicine.
[46] S. Agnandji,et al. Interleukin-21 is associated with IgG1 and IgG3 antibodies to erythrocyte-binding antigen-175 peptide 4 of Plasmodium falciparum in Gabonese children with acute falciparum malaria. , 2008, European cytokine network.
[47] P. Rosenthal,et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. , 2006, The Journal of infectious diseases.
[48] A. Tartar,et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. , 1994, Blood.
[49] W H TALIAFERRO,et al. Acquired immunity in malaria. , 1948, Abstracts. International Congress on Tropical Medicine and Malaria.